1. Home
  2. ASNS vs MYNZ Comparison

ASNS vs MYNZ Comparison

Compare ASNS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actelis Networks Inc.

ASNS

Actelis Networks Inc.

HOLD

Current Price

$0.56

Market Cap

10.9M

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.24

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASNS
MYNZ
Founded
1998
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
8.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ASNS
MYNZ
Price
$0.56
$1.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$50.00
$14.00
AVG Volume (30 Days)
2.1M
188.9K
Earning Date
11-14-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,367,000.00
$659,935.00
Revenue This Year
N/A
N/A
Revenue Next Year
$208.63
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.92
52 Week High
$17.80
$8.20

Technical Indicators

Market Signals
Indicator
ASNS
MYNZ
Relative Strength Index (RSI) 30.02 54.02
Support Level $2.55 $1.00
Resistance Level $3.10 $1.15
Average True Range (ATR) 0.33 0.08
MACD -0.35 0.03
Stochastic Oscillator 2.49 76.27

Price Performance

Historical Comparison
ASNS
MYNZ

About ASNS Actelis Networks Inc.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: